Novel protein biomarker for breast and lung cancer
Professor El-Tanani is leading research into novel targeted therapeutics (Ran-inhibitors) for the treatment of triple negative breast cancer and to reverse chemotherapy resistance in lung cancer.
Professor El-Tanani is leading research into novel targeted therapeutics (Ran-inhibitors) for the treatment of triple negative breast cancer and to reverse chemotherapy resistance in lung cancer.
A new technique that could help improve diagnosis of vision disorders has been successfully tested at Bradford
Professor El-Tanani is leading research into novel targeted therapeutics (Ran-inhibitors) for the treatment of triple negative breast cancer and to reverse chemotherapy resistance in lung cancer.
A new technique that could help improve diagnosis of vision disorders has been successfully tested at Bradford
Law students are putting what they’ve learnt into practice with new partnerships providing legal advice to all.